This week: menopause became the peptide market's newest target, injectable safety stories landed in the same news cycle, and the GLP-1 vision scare gets the grade we promised.

Let's go. ☕

The menopause peptide moment

That quote, or some version of it, is everywhere. The evidence is moving more slowly.

Menopause peptides went mainstream

The New York Post recently profiled women using gray-market peptides for menopause symptoms, while Women's Health went inside the DIY peptide market and found women using compounds like BPC-157, GHK-Cu, and ipamorelin for hormonal, reproductive, recovery, and anti-aging concerns.

The pitch works because the need is real. Women dealing with poor sleep, fatigue, brain fog, body-composition changes, or disappointing menopause care are an easy audience for something marketed as newer and more personalized. But none of these peptides has clinical-trial evidence establishing it as a treatment for menopause symptoms.

Tesamorelin, for example, has real human data and an FDA-approved use. It just is not menopause. Its approved indication is reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

Then came the safety stories

Two different stories landed around the same time. The FDA and CDC are investigating illnesses linked to compounded injectable glutathione made with an ingredient that was not appropriate for injection. More than 25 people became ill, including several hospitalizations. That alert was not specifically about sermorelin or tesamorelin.

Separately, Forbes reported severe reactions in people using gray-market products sold as sermorelin and tesamorelin. Because those products were not tested afterward, it is impossible to know whether the reaction came from the intended peptide, the dose, contamination, or something else in the vial. The FDA has also raised safety concerns around compounded CJC-1295, ipamorelin, and injectable GHK-Cu.

The point is not that every peptide injection is dangerous. It is that source, manufacturing quality, approved use, and actual human evidence matter.

What actually is approved for menopause

Women do have evidence-based options. Menopausal hormone therapy remains an established treatment category. And the nonhormonal toolbox now includes fezolinetant and elinzanetant, both FDA-approved for moderate-to-severe vasomotor symptoms due to menopause.

That does not mean every option fits every woman. It means the approved menopause toolkit is bigger than the peptide marketing makes it sound.

What to know

• Ask two questions: what regulatory category is this product in, and what human evidence supports using it for menopause specifically?
• A prescription does not automatically mean FDA-approved.
• A licensed pharmacy does not turn a compounded medication into an FDA-approved menopause treatment.

The peptide menu is getting longer. So is the evidence-based menopause toolkit. Only one tends to make it into the ad.

“GLP-1s cause blindness.”

What the evidence says. The condition at the center of the story is NAION, a rare optic-nerve disorder that can cause sudden vision loss. A 2024 study reported an association between semaglutide and NAION, although it could not prove causation. Later studies found a smaller and less consistent signal.

European regulators concluded in 2025 that NAION should be considered a very rare side effect of semaglutide, estimated at up to 1 case per 10,000 people treated. The current U.S. Wegovy label still does not list NAION as a warning or adverse reaction.

So two things can be true: the signal is real enough to study, and the event remains rare. This is also primarily a semaglutide signal, not evidence that every GLP-1 drug commonly causes blindness. Sudden vision loss or rapidly worsening eyesight deserves prompt medical evaluation, regardless of medication.

Worth your inbox

Researching health for yourself is one job. Doing it for an aging parent at the same time is two. GrayBrief is a plain-English education resource for adult children navigating elder care: what to ask, what to watch for, and what nobody tells you until it's urgent. If that's your season of life, it's worth a look.

Not necessarily. A prescription means a licensed prescriber ordered the medication. It does not mean the FDA approved that product, or approved it for the reason you are using it.

Sermorelin has an unusual history. FDA-approved Geref products existed years ago, but the manufacturer discontinued them and asked the FDA to withdraw the approvals. The FDA later reviewed the available information and determined that the products had not been withdrawn because of safety or effectiveness concerns. There is no currently marketed FDA-approved sermorelin product, and sermorelin is not FDA-approved for sleep, energy, or menopause symptoms.

So I would ask: what exactly is the product, where is it coming from, and what human evidence supports using it for my symptoms? A prescription and a licensed pharmacy matter. They just do not make a compounded medication an FDA-approved menopause treatment.

Mais, PharmD, Medical Reviewer, Pep in Her Step

• GLP-1s and PCOS: a new peer-reviewed scoping review finally gives this long-promised piece its anchor.
• Your GLP-1 and your other medications: why slowed digestion may change how pills absorb.
• The muscle question, answered properly: protein, lifting, and what the scans actually show.